Dr. Frey on the Utility of CART22-65s with huCART19 in Relapsed/Refractory ALL

Video

Noelle V. Frey, MD, MSCE, discusses the results of a study evaluating the utility of co-administered CART22-65s and huCART19 in relapsed/refractory acute lymphoblastic leukemia that were presented at the 2021 ASH Annual Meeting & Exposition.

Noelle V. Frey, MD, MSCE, Constance and Sankey Williams Associate Professor, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, discusses the results of a study evaluating the utility of co-administered CART22-65s and huCART19 in relapsed/refractory acute lymphoblastic leukemia (ALL) that were presented at the 2021 ASH Annual Meeting & Exposition.

Regarding safety, the results of the phase 1 study showed that 2 of the 13 patients infused with CART22-65s and huCART19 developed toxicity before the 28-day assessment. Of these patients, 1 died from therapy-related complications, and 1 developed rapidly progressive disease, Frey said. However, the 11 patients who were evaluable at the 1-month time point allachieved complete remissions that were minimal residual disease negative, Frey explains.

Overall, the co-administered products were well tolerated; cytokine release syndrome (CRS) and neurotoxicity were observed but manageable, Frey said. Hemophagocytic lymphohistiocytosis-like syndrome (HLH) was a unique toxicity attributed to CART22-65s. HLH is clinically distinct from traditional CRS and has been noted in CART22-65s products before, Frey adds. The toxicity was mitigated in the patient who developed HLH, and they were able to continue with a sustained remission, Frey concludes.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD